Dear Dr. Wolfe:

Please refer to your supplemental new drug application dated May 19, 2005, received May 20, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Advil Liquigels and Advil Migraine (200 mg ibuprofen) capsules.

Your submission of February 15, 2006 constituted a complete response to our November 10, 2005 action letter.

This supplemental new drug application provides for the addition of the warning statement “Ask a doctor or pharmacist before use if you are [bulleted] taking aspirin for heart attack or stroke, because ibuprofen may decrease this benefit of aspirin.” to the Drug Facts label for the 2-, 4-, 20-, 40-, 80-, 135-, and 180-count carton labels for Advil Liquigels and the 20-, 40-, and 80-count carton labels for Advil Migraine.

We have completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text submitted February 15, 2006. We note that the labeling in your supplemental application (018) approved on February 26, 2006 supersedes this application, with the exception of the warning statement noted above.

The final printed labeling (FPL) must be identical to the draft labeling approved on February 8, 2006 under supplement 018 for Advil Liquigels, and Advil Migraine with the addition of the identical statement noted above submitted as text for the carton labels under supplement 016 on February 15, 2006, and must be formatted in accordance with the requirements of 21 CFR 201.66.

Please submit an electronic version of the FPL for all stock keeping units according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format - NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "FPL for approved supplements NDA 20-402/S-016, S-018” Approval of this submission by FDA is not required before the labeling is used.
If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
WO 22, Room 4447
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Neel Patel, Regulatory Project Manager, at (301) 796-0970.

Sincerely,

[See appended electronic signature page]

Andrea Leonard-Segal, MD
Director
Division of Nonprescription Clinical Evaluation
Office of Nonprescription Products
Center for Drug Evaluation and Research